William Matsui

The role of growth factors in the activity of pharmacological differentiation agents.

Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation.

Characterization of clonogenic multiple myeloma cells.

Cancer stem cells: are we missing the target?

Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins.

Association of Foxp3 regulatory gene expression with graft-versus-host disease.

Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.

Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.

Do neoplastic stem cells underlie the pathogenesis of cutaneous lymphomas?

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.

The paradox of response and survival in cancer therapeutics.

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.

Strategies to eliminate cancer stem cells: clinical implications.

Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.

Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Therapeutic implications of leukemic stem cell pathways.

Cancer Stem Cells: From Bench to Bedside.

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Multiple myeloma cancer stem cells.

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Cancer stem cells in multiple myeloma.

Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH.

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.

Circulating clonotypic B cells in classic Hodgkin lymphoma.

GLI1 是直接的 EWS FLI1 基因转录目标。

Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.

Higher serum folate levels are associated with a lower risk of atopy and wheeze.

Smoothening the controversial role of hedgehog in hematopoiesis.

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.

Cancer stem cells: controversies in multiple myeloma.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Urothelial carcinoma: stem cells on the edge.

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.

Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis.

Targeting Hedgehog--a cancer stem cell pathway.

Mantle cell lymphoma activation enhances bortezomib sensitivity.

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Tumor-initiating cells are rare in many human tumors.

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.

Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Characterization of chronic myeloid leukemia stem cells.

Hedgehog signaling in hematopoiesis.

Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.

Concise review: Emerging concepts in clinical targeting of cancer stem cells.

Development and maintenance of cancer stem cells under chronic inflammation.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels.

Perspective: A model disease.

Autologous stem cell transplantation and multiple myeloma cancer stem cells.

Cancer stem cells: relevance to clinical transplantation.

Biological and clinical relevance of stem cells in pancreatic adenocarcinoma.